Rege Nephro ^Private

Rege Nephro is a biotech company that specializes in the research, development, production, and sale of renal disease therapeutics. They have successfully achieved stable production of nephron progenitor cells using innovative technology developed by Kyoto University Professor Kenji Osafune. Rege Nephro is currently focused on investigating and developing regenerative medicine products for kidney diseases using these cells, as well as producing kidney organoids for nephrotoxicity screening in drug discovery. The company has been recognized for its achievements and was selected as one of Forbes JAPAN's "Next Generation Startups to Watch in 2024."